Austrian survey of treating heart failure - AUSTRIA

European Journal of Heart Failure

Volumn 6, Issue 7, 2004, Pages 947-952

  Fruhwald, Friedrich M ^a   Rehak, Peter ^a   Maier, Robert ^a   Watzinger, Norbert ^a   Wonisch, Manfred ^a   Klein, Werner ^a  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

Chronic heart failure; Survey; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; LISINOPRIL; RAMIPRIL; SPIRONOLACTONE;

ADULT; AGED; AUSTRIA; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HEART FAILURE; HUMAN; INTERNAL MEDICINE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OUTPATIENT; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRIVATE PRACTICE; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AUSTRIA; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; MEDICAL RECORDS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROSPECTIVE STUDIES;

EID: 8844260440     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2004.02.004     Document Type: Review

References (18)

1. Stewart S., MacIntyre K., Hole D.J., Capewell S., McMurray J.J.V. More malignant than cancer? Fiver-year survival following a first admission for heart failure. Eur J Heart Fail. 3:2001;315-322
2. Mosterd A., Hoes A.W., deBruyne M.C., Deckers J.W., Linker D.T., Hofman A., et al. Prevalence of heart failure and left ventricular dysfunction in the general population. Eur Heart J. 20:1999;447-455
3. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 22:2001;1527-1560
4. Wonisch M., Fruhwald F.M., Maier R., Watzinger N., Hoedl R., Kraxner W., et al. Management of congestive heart failure by general practitioners - results from the Styrian heart failure survey. J Clin Basic Cardiol. 4:2001;145-148
5. Cleland JGF, Cohen-Solal A, Cosin Aguilar J, Dietz R, Eastaugh J, Follath F, et al. for the IMPROVEMENT-investigators. Management of heart failure in primary care (the IMPROVEMENT of heart failure programme): an international survey. Lancet 2002;360:1631-1639
6. Cleland J.G.F., Swedberg K., Follath F., Komajda M., Cohen-Solal A., Aguilar J.C., et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 24:2003;442-463
7. The Study Group of Diagnosis of the Working Group on Heart Failure of the ESC, Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003;24:464-474
8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival study (CONSENSUS). N Engl J Med. 316:1987;1429-1435
9. Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310
10. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 325:1991;293-302
11. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, et al. on behalf of the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-2318
12. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
13. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet. 353:1999;9-13
14. MERIT-HF-Study group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 353:1999;2001-2007
15. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. for the COPERNICUS study group. N Engl J Med 2001;344:1651-1658
16. Pitt B, Zannad B, Remme WJ, Cody R, Castaigne A, Perez A, et al. for the RALES investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717
17. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study (ELITE II). Lancet 2000;355:1582-1587
18. Cohn JN, Tognoni G for the Val-HEFT investigators. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675